Isoflavone supplementation reduces low-density lipoprotein cholesterol levels in postmenopausal women

Main Article Content

Yenny Yenny
Pusparini Pusparini

Abstract

Background
Cardiovascular disease is the main cause of death in postmenopausal women. This study aimed at evaluating the effect of soy isoflavone supplementation on plasma lipid profile in postmenopausal women, since this effect is still unclear.

Methods
A double-blind randomized placebo-controlled trial was conducted from January 2010 until February 2011. In total 180 postmenopausal women were randomized into an isoflavone group and a control group of 90 subjects each. The isoflavone group received tablets containing 100 mg soy isoflavones and 500 mg calcium carbonate, while the control group received 500 mg calcium carbonate only. Supplementation was given once daily for 1 year. Plasma lipid levels [triacylglycerol, total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterols] were assessed at baseline, and after 6 and 12 months of supplementation using an enzymatic colorimetric method (Cobas c 111, Roche). Independent t-test was used for data analysis.

Results
Baseline subject characteristics and lipid profile in the two groups were comparable. In the isoflavone and control groups after 6 months of supplementation LDL cholesterol levels were 124.9 ± 35.2 mg/dL vs 112 .7 ± 29.7 mg/dL (p=0.013*), respectively, and after 12 months 116.9 ± 31.7 mg/dL vs 109.1 ± 29.8 mg/dL (p=0.086). There were no significant differences in the other lipid levels at 6 and 12 months.

Conclusions
Soy isoflavone supplementation for 6 months was capable of significantly reducing LDL cholesterol levels in postmenopausal women. No significant changes in total cholesterol, triacylgycerol, and HDL cholesterol were found after isoflavone supplementation.

Article Details

How to Cite
Yenny, Y., & Pusparini, P. (2013). Isoflavone supplementation reduces low-density lipoprotein cholesterol levels in postmenopausal women. Universa Medicina, 32(3), 197–207. https://doi.org/10.18051/UnivMed.2013.v32.197-207
Section
Review Article

References

Heron M. Deaths: leading causes for 2009. National Vital Statistics Reports 2012;61:1-96.

Cignarella A, Kratz M, Bolego C. Emerging role of estrogen in the control of cardiometabolic disease. Trends Pharmacol Sci 2010;31:183-9.

The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidemias. Eur Heart J 2011:32:1769-818.

Tandon VR, Mahajan A, Sharma S, Sharma A. Prevalence of cardiovascular risk factors in postmenopausal women: a rural study. J Med Life Health 2010;1:26-9.

Gil-Izquierdo A, Penalvo JL, Gil JI, Medina S, Horcajana MN, Lafay S, et al. Soy isoflavones and cardiovascular disease epidemiological, clinical and omics perspectives. Curr Pharm Biotechnol 2012;13:624-31.

Nagaraju GP, Zafar SF, El-Rayes BF. Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases. Nutr Rev 2013;71:562-72.

Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer 2006;55:1-12.

De Kleijn MJJ, Van Der Schouw YT, Wilson PWF, Adlercreutz H, Mazur W, Grobbee DE, et al. Intake of dietary phytoestrogens is low in postmenopausal women in the United States : the framingham study. J Nutr 2001;154:434-41.

Pilsakova L, Riecansky I, Jagla F. The physiological action of isoflavone phytoestrogen. Physiol Res 2010;59:651-64.

Orgaard A, Jensen L. The effects of soy isoflavones on obesity. Exp Biol Med (Maywood) 2008;233:1066-80.

Patel RP, Barnes S. Isoflavones and PPAR signaling: a critical target in cardiovascular, metastatic, and metabolic disease. PPAR Res 2010. Article ID 153252, 10 pages. doi:10.1155/2010/153252.

Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr 2005;81:397-408.

Prediger CCC, Olinto MTA, Nacul LC, Ziegler DR, Pattussi MP. Effect of soy protein containing isoflavones on women’s lipid profile: a meta-analysis. Rev Nutr Campinas 2011;24:161-72.

Qin Y, Niu K, Zeng Y, Liu P, Yi L, Zhang T, et al. Isoflavones for hypercholesterolaemia in adults. Cochrane Database Syst Rev. 2013 Jun 6;6:CD009518. doi: 10.1002/14651858. CD009 518.pub2. Review.

Kementerian Kesehatan. Status gizi dewasa menurut indeks massa tubuh: Riset Kesehatan Dasar (Riskedas) 2010. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI tahun 2010. Available at: http://www.riskesdas.litbang. depkes.go.id/download/TabelRiskesdas2010.pdf. Accessed August 6, 2013.

National Choletsrol Education Program National Institute of Health. Detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel III). National Institute of Health;2002.

Yang TS, Wang SY, Yang YC, Su CH, Lee FK, Chen SC, et al. Effects of standardized phytoestrogen on Taiwanese menopausal women. Taiwan J Obstet Gynecol 2012;51:229-35.

Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2007;85:1148-56.

Mangano KM, Hutchins-Wiese HL, Kenny AM, Walsh SJ, Abourizk RH, Bruno RS, et al. Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women: a randomized controlled trial. Nutr Res 2013;33: 1026-33.

Jassi HK, Jain A, Arora S, Chitra R. Effect of soy proteins vs soy isoflavones on lipid profile in postmenopausal women. Indian J Clin Biochem 2010;25:201-7.

Shidfar F, Ehramphosh E, Heydari I, Haghighi L, Hosseini S, Shidfar S. Effects of soy bean on serum paraoxonase 1 activity and lipoproteins in hyperlipidemic postmenopausal women. Int J Food Sci Nutr 2009;60:195-205.

Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans: review of 97 bioavailability studies. Am J Clin Nutr 2005;81: 230S-42S.

Ho SC, Chen YM, Ho SS, Woo JL. Soy isoflavone supplementation and fasting serum glucose and lipid profile among postmenopausal Chinese women: a double-blind, randomized, placebo-controlled trial. Menopause 2007;14: 905-12.

Rios DR, Rodrigues ET, Cardoso AP, Montes MB, Franceschini SA, Toloi MR. Lack of effects of isoflavones on the lipid profile of Brazilian postmenopausal women. Nutrition 2008;24:1153-8.

Steinberg FM, Murray MJ, Lewis RD, Cramer MA, Amato P, Young RL, et al. Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr 2011;93:356-67.

North American Menopause Society. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause 2011;18:732-53. doi: 10.1097gme.0b013e31821 fc8e0.

Lampe JW, Chang JL. Interindividual differences in phytochemical metabolism and disposition. Semin Cancer Biol 2007;17:347-53.

Hall WL, Vafeiadou K, Hallund J, Bugel S, Reimann M, Koebnick C, et al. Soy isoflavone enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production. Am J Clin Nutr 2006;83:592-600.

Sack FM, Lichtenstein A, Van Horn L, Harris W, Harris W, Kris-Etherton P, et al. Soy protein, isoflavones and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006;113:1034–44.